Iktos Adds a Servier Deal to Its EIC Accelerator Robotics Push

Designing a drug molecule on a computer is fast; making and testing it is not. Drug discovery often takes more than a decade and costs upwards of €1.3 billion, and about 90% of candidates fail in clinical trials, according to the CORDIS summary of Iktos's EIC project. The Paris company started in 2016 by selling generative AI software that proposes new molecules. It has since added robots that synthesise them and, through an acquisition, a lab that tests them.

The EIC Accelerator selected Iktos at its October 2024 cut-off under the challenge for human-centric generative AI made in Europe, and CORDIS records a grant of €2,499,616 for AIR-3D from August 2025 to July 2027. The goal is a closed loop in which AI designs, robots make and automated assays test molecules, cutting the discovery phase from an average of five years to about two. In January 2026 Servier signed a multi-target collaboration built on that platform, with a potential value above €1 billion.

From software to a lab

Iktos was registered in Paris on 17 October 2016, according to the French company register, which lists Yann Gaston-Mathé as chief executive, Roman Fleck as board chair and the Debiopharm Innovation Fund as a board member. The register puts the workforce at 50 to 99 employees in 2024 and shows revenue of €4.46 million and a net loss of €1.31 million for 2022, the last year it publishes.

Its first business was software: generative AI that proposes molecules for pharmaceutical clients, with more than 50 academic and industrial collaborations by 2023. In March 2023 it raised a €15.5 million Series A led by M Ventures and the Debiopharm Innovation Fund with Omnes Capital, partly to launch Iktos Robotics, "a drug discovery platform which combines artificial intelligence and automation of chemical synthesis", according to Scientific Computing World.

In July 2024 Iktos bought Synsight, a biotech at Evry Genopole that screens for molecules acting on protein-protein and RNA-protein interactions inside cells, with a technology licensed from Inserm. The deal brought in-house the biological testing of the compounds Iktos's robots make, which it had outsourced before, Drug Development and Delivery reported. The price was not disclosed.

AIR-3D: closing the loop

Iktos announced the award on 20 February 2025 as a €2.5 million grant "with the option for additional €5M funding", to combine generative AI, robotics and high-precision biological screening. The Commission signed the grant on 25 July 2025. CORDIS describes a closed-loop, data-informed discovery platform and shows no periodic report yet, so there is no public account of the first project year.

The Servier deal

On 8 January 2026 Iktos and Servier announced a multi-year collaboration on multiple undisclosed small-molecule targets in oncology and neurology, according to M Ventures. Iktos will use its generative AI and AI-orchestrated robotics to design, synthesise and optimise molecules; Servier will test them in its own assays and run preclinical and clinical development. The total potential value could exceed €1 billion, including upfront payments, research funding and milestones. Milestone payments are only due if programmes progress, and the upfront payment was not disclosed.

1. Robotic synthesis platformIn useNamed as part of the platform in the Servier deal.
2. In-house biological screeningAcquiredSynsight, July 2024.
3. Closed-loop autonomous discoveryNot reportedNo periodic report or cycle-time data published.
4. Discovery in about two yearsToo earlyThe project runs to July 2027; no candidate from the loop disclosed.

Funding and the EIC option

Iktos has announced no equity round since the 2023 Series A. Whether the €5 million option attached to the EIC award has been used, and in what form, is not public, and the French register shows no accounts after 2022. Partnerships such as Servier's bring upfront and research payments that can fund the platform without new equity.

Generative AI made in Europe

The EIC chose AIR-3D under its challenge for human-centric generative AI made in Europe. Iktos is a French company, and its largest announced partner, Servier, is a French pharmaceutical group, so both the technology and its first large application stay in Europe. The test for the EIC's bet is whether the loop produces drug candidates faster than conventional chemistry, which only clinical programmes from the Servier deal will show.